CVE-2023-33366

CVE-2023-33366 is a high-severity vulnerability in Supremainc Biostar 2 with a CVSS 3.x base score of 8.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-89.

Key facts

Description

A SQL injection vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows authenticated users to inject arbitrary SQL directives into an SQL statement and execute arbitrary SQL commands.

Frequently asked questions

What is CVE-2023-33366?
A SQL injection vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows authenticated users to inject arbitrary SQL directives into an SQL statement and execute arbitrary SQL commands.
How severe is CVE-2023-33366?
CVE-2023-33366 has a CVSS 3.x base score of 8.8, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2023-33366 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (44th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-33366?
CVE-2023-33366 affects Supremainc Biostar 2. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-33366?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2023-33366 published?
CVE-2023-33366 was published on 2023-08-03 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Supremainc Biostar 2

All CVEs affecting Supremainc Biostar 2 →

Other CWE-89 (SQL Injection) vulnerabilities

Browse all CWE-89 (SQL Injection) vulnerabilities →